Successful BCMA-CAR T-cell salvage therapy in a patient with idiopathic inflammatory myositis relapsing after CD19-CAR T-cell therapy (EULAR 2025) - Mar 30, 2025 - Abstract #POS0089; M374; Pres time: Jun 12, 2025; 10:05 AM - 10:12 AM; Location: Poster Tour II; "The patient experienced a CMV-viremia under daratumumab, which was successfully treated with oral valganciclovir. Due to ongoing disease activity, plasma cell-targeting BCMA-CAR T-cell therapy was performed (Idecabtagene vicleucel, Bristol Myers Squibb). The patient experienced grade 1 cytokine release syndrome (CRS) on day 3, which resolved upon a single dose of the anti-interleukin-6 receptor monoclonal antibody tocilizumab. No neuro- or hematotoxicity were observed and, supported by a 100-day prophylaxis with letermovir, no CMV-reactivation occurred. BCMA-CAR T-cells expanded, cleared B cells in circulation and plasma cells in lymphoid tissue, reduced autoantibody levels, and re-induced stable drug-free remission with normalization of CK within three months. Learning points for clinical practice: These data demonstrate that (i) a switch of CAR T-cell target can restore drug-free remission after relapse of AID after the first CAR T-cell treatment, (ii)..."
CAR T-Cell Therapy • Clinical • Immunology • Interstitial Lung Disease • Myositis • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Rheumatology • Transplant Rejection • IL6R
|
|
A. Wirsching 1,2; F. Müller 2,3; M. Hagen 1,2; S. Völkl 2,3; C. Tur 1,2; G. Raimondo 1,2; J. Taubmann 1,2; L. Bucci 1,2; S. Kretschmann 2,3; M. Aigner 2,3; M. Eckstein 4; S. Spörl 2,3; S. Kharboutli 2,3; S. Boeltz 1,2; A. Atzinger 5; A. Mackensen 2,3; G. Schett, R. Grieshaber-Bouyer 1,2
|